The challenge of thrombophilia in maternal-fetal medicine

Article Abstract:

All pregnant women with a personal or family history of venous thromboembolism should be tested for gene mutations that can cause this condition. Venous thromboembolism occurs when blood clots form in large veins and then travel to other parts of the body. This is dangerous because the clot can block the flow of blood. Pregnant women have a greater risk of venous thromboembolism than non-pregnant women. Pregnant women who test positive for some gene mutations that can cause this condition can be treated with low-molecular-weight heparin.

Care and treatment, Editorial, Pregnant women

---

Increased frequency of genetic thrombophilia in women with complications of pregnancy

Article Abstract:

A blood clotting disorder may increase the risk of obstetrical complications in some pregnant women. These complications include preeclampsia, stillbirth, fetal growth retardation and placental abnormalities. Researchers analyzed blood samples for evidence of gene mutations in 110 women who had an obstetrical complication and 110 who had a normal pregnancy. Half of the women with obstetrical complications had a gene mutation that caused blood clotting abnormalities, compared to 17% of the women with a normal pregnancy.

Health aspects, Gene mutations, Gene mutation, Blood clotting disorders, Blood coagulation disorders, Genetic aspects, Pregnancy, Complications of, Pregnancy complications

---

A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma

Article Abstract:

Low-molecular-weight heparin seems to be more effective in preventing thromboembolism in patients with major injuries than low-dose heparin. Thromboembolism occurs when a blood clot forms, travels through the bloodstream and cuts off the blood supply to an organ. Of 344 people admitted to a trauma center with severe injuries, 173 received low-dose heparin for up to 14 days and 171 received a form of low-molecular-weight heparin called enoxaparin. Enoxaparin reduced the incidence of thromboembolism by 30%.

Wounds and injuries, Injuries, Dosage and administration, Heparin

Similar abstracts:

• Abstracts: Suicide acceptable on operatic stage, not in real life. Future of genetics: watch to avoid Titanic mistakes. Mandated use of PA in surgery raises two concerns
• Abstracts: The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists
• Abstracts: The role of early HIV infection in the spread of HIV through populations. Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1?
• Abstracts: Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias
• Abstracts: Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.